Clinical Research. Parkinson's Disease

Created in partnership with Parkinson’s UK, one of the world’s largest charity funders of Parkinson’s research, the Critical Path for Parkinson’s Consortium (CPP) was launched on October 14, 2015. This is a global collaboration that promises to pave the path to new treatments for Parkinson’s. By facilitating collaboration among scientists from the biopharmaceutical industry, academic institutions, government agencies, and patient-advocacy associations, CPP fosters consensus and data-driven research to increase efficiency, safety, and speed in developing new therapies.

Traditionally, Parkinson’s has been viewed as a disorder in which individuals don’t have enough of a chemical called dopamine because specific nerve cells inside their brain have died. Current research indicates that the processes that lead to dopamine deficit start much earlier (decades), making it a pressing need to increase the understanding of Parkinson’s progression.